Teleflex Q3 Beats, Lifts 2026 Adjusted EPS Guidance to $7.50-$7.75
TFX sits 41% above its 52-week low of $100.18.
Summary
Teleflex grew Q3 adjusted EPS 39.2% to $2.63 and raised 2026 adjusted EPS guidance to $7.50-$7.75, while holding constant-currency revenue growth guidance at 3.5%-4.5%. Buybacks since July 1 total $350 million, with $400 million left on the authorization.
Key Events · Earnings and Guidance · TFX
-
Q3 Adjusted EPS Jumps 39.2%
Adjusted diluted EPS from continuing operations came in at $2.63 versus $1.89 a year ago; GAAP diluted EPS was $1.30 versus $(1.32).
-
2026 Adjusted EPS Guidance Raised
Full-year adjusted diluted EPS from continuing operations guidance was lifted to $7.50-$7.75, with pro forma adjusted constant currency revenue growth held at 3.5%-4.5%.
-
Margins Expand on Tariff Refunds
Adjusted gross margin of 66.8% and adjusted operating margin of 25.0% included a $16.5 million IEEPA tariff refund benefit recognized in Q3 2026.
-
$350M Buyback Completed Since July
2.7 million shares were repurchased at an average $128.96, leaving $400 million available under the $1 billion authorization, to be funded with divestiture proceeds.
Analysis · TFX · Industrial Applications And Services
A clean quarter from continuing operations gave management room to raise guidance. Adjusted EPS of $2.63 climbed 39.2% from $1.89 a year ago, with adjusted gross margin at 66.8% and adjusted operating margin at 25.0%, helped by $16.5 million of IEEPA tariff refunds booked in the quarter. Full-year adjusted EPS guidance now sits at $7.50-$7.75, while pro forma constant-currency revenue growth is held at 3.5%-4.5%; GAAP revenue growth guidance was cut to 13.2%-14.2% purely on a smaller FX tailwind. Since July 1 the company has repurchased $350 million of stock (2.7 million shares at an average $128.96), leaving $400 million on its $1 billion authorization. The remaining buyback and about $800 million of debt paydown are to be funded by proceeds from the pending Acute Care and Interventional Urology divestiture, still targeted to close by year-end but at risk of slipping into 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TFX was trading at $141.31 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $100.18 to $150.04. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.